p450 - publications

Predict more p450 - ligand interactions now!


1. Hepatogastroenterology. 2012 May-Jun;59(115):805-8. doi: 10.5754/hge09722.

Western Blotting Analysis for Quantitative Detection of CYP2C19 Expression in
Liver Tissues in the Setting of Living Donor Liver Transplantation.

Chiu KW, Nakano T, Tseng HP, Cheng YF, Jawan B, Eng HL, Goto S, Chen CL.

Background: The cytochrome P450 (CYP) drug-metabolizing enzymes play an important
role in cellular metabolism. Therapeutic failure or drug toxicity in the period
after liver transplantation (LT) is influenced by the drug metabolizing capacity
of the graft. The expression levels of CYP2C19 enzyme are often used as an
indicator of the functioning of the CYP system. The aim of the present study was
to assess the CYP2C19 protein expression in the setting of living donor liver
transplantation (LDLT) by using western blotting analysis. Methodology: We
performed CYP2C19 genotyping of liver biopsy samples obtained from 24 donors and
8 recipients each in the pre- and post-LT periods, after which we analyzed the
CYP enzyme activity by using western blotting analysis. Results: The
CYP2C19/β-actin ratio, which was an indicator of CYP expression, was 61.75%
(23-100%) in donors, 59.13% (15-100%) in pre-LT recipients and 46.71% (12-67%) in
post-LT recipients (p>0.05). The CYP2C19 expression levels associated with
different genotypes were as follows: homozygous extensive metabolizers (HomEMs;
n=24), 56.63±24.74%; heterozygous extensive metabolizers (HetEMs; n=15),
63.0±25.14% and poor metabolizers (PMs; n=1), 82.0% (p>0.05). Conclusions:
Western blotting analysis showed low CYP2C19 protein expression not only in
samples from the pre- and post-LT recipients but also from the donors.

PMID: 22469723 [PubMed - in process]